Novo Nordisk® logo
NovoCare® Savings | Coverage | Support NovoCare® Savings | Coverage | Support
Novo Nordisk® logo

Growth Hormone Programs

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, 15 mg pens
  • Norditropin® (somatropin) injection 5 mg, 10 mg, 15 mg, 30 mg pens

Patient Assistance Program (PAP) Eligibility Requirements:

Patients who meet program eligibility criteria and financial need requirements are eligible to receive a free supply of Sogroya® or Norditropin® for up to one (1) year with requalification process to occur thirty (30) days prior to PAP expiration.

  • You must be a US citizen or legal resident
  • Your total household income must be at or below 400% of the federal poverty level (FPL) after inclusion of Sogroya® or Norditropin® estimated cost deduction. Visit the NeedyMeds website, which lists the current FPL guidelines
  • You must have been prescribed therapy for a diagnosis that is an FDA-approved indication for Sogroya® or Norditropin®
  • You cannot have or qualify for government benefit coverage, including any federal, state, or local program such as Medicare or Medicaid:
    • Exceptions include:
      • Government beneficiary with diagnosis or therapy exclusion
      • Patients who are eligible for Department of Veterans Affairs (VA) prescription benefits or Medicaid must have applied for and been denied enrollment, including exhaustion of all appeals
      • Patients who are Medicare eligible and do not have Medicare Part D coverage who have applied for and been denied Extra Help/Low Income Subsidy (LIS). To apply for LIS, please contact the Social Security Administration at 1‑800‑772‑1213 (TTY 1‑800‑325‑0778) or go to ssa.gov/benefits/medicare/prescriptionhelp/

JumpStart™ and Interim Program Eligibility

Patients who have been prescribed a Novo Nordisk growth hormone medication for an FDA-approved indication and who have commercial insurance may be eligible to receive a limited supply of free product from JumpStart™ or the Interim Program. Please note:

  • JumpStart™ is only available for patients who are prescribed Sogroya®. JumpStart™ is not available for patients who are prescribed Norditropin®
  • The Interim Program is available for patients who are prescribed either Sogroya® or Norditropin®

Patients who participate in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to participate in JumpStart™ or the Interim Program.

JumpStart™ and Interim Program product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.

Novocare_Norditropin_v01

Important Safety Information for Norditropin®

Do not use Norditropin® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing (respiratory) problems
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea
  • you have cancer or other tumors
  • you are allergic to somatropin or any of the ingredients in Norditropin®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes (diabetic retinopathy)
  • you are a child with closed bone growth plates (epiphyses)

What is Norditropin®?

Norditropin® (somatropin) injection 5 mg, 10 mg, 15 mg or 30 mg is a prescription medicine that contains human growth hormone and is used to treat:

  • children who are not growing because of low or no growth hormone
  • children who are short (in stature) and who have Noonan syndrome, Turner syndrome, or were born small (small for gestational age-SGA) and have not caught-up in growth by age 2 to 4 years
  • children who have Idiopathic Short Stature (ISS)
  • children who are not growing who have Prader-Willi syndrome (PWS)
  • adults who do not make enough growth hormone

Important Safety Information

Before taking Norditropin®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had heart or stomach surgery, trauma or serious breathing (respiratory problems)
  • have had a history of problems breathing while you sleep (sleep apnea)
  • have or have had cancer or any tumor
  • have diabetes
  • are pregnant or breastfeeding, or plan to become pregnant or breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Norditropin® may affect how other medicines work, and other medicines may affect how Norditropin® works.

How should I use Norditropin®?

  • Use Norditropin® exactly as your health care provider tells you to
  • Do not share your Norditropin® pens and needles with another person even if the needle has been changed. You may give another person an infection or get an infection from them.

What are the possible side effects of Norditropin®?

Norditropin® may cause serious side effects, including:

  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma or serious breathing (respiratory) problems
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems including sleep apnea
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Contact the healthcare provider if you or your child start to have headaches, or have changes in behavior, changes in vision, or changes in moles, birthmarks, or the color of your skin
  • new or worsening high blood sugar (hyperglycemia) or diabetes
  • increase in pressure in the skull (intracranial hypertension). If you or your child has headaches, eye problems, nausea or vomiting, contact the healthcare provider
  • serious allergic reactions. Get medical help right away if you or your child has the following symptoms: swelling of your face, lips, mouth or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, or sweating
  • your body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your joints or muscles or nerve problems that cause pain, burning, or tingling in the hands, arms, legs and feet. Tell your healthcare provider if you have any of these signs or symptoms of fluid retention.
  • decrease in a hormone called cortisol. Tell your or your child’s healthcare provider if you or your child has darkening of the skin, severe fatigue, dizziness, weakness or weight loss
  • decrease in thyroid hormone levels
  • hip and knee pain or a limp in children (slipped capital femoral epiphysis)
  • worsening of pre-existing curvature of the spine (scoliosis)
  • severe and constant abdominal pain can be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain.
  • loss of fat and tissue weakness in the area of skin you inject
  • increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood

The most common side effects of Norditropin® include:

  • injection site reactions and rashes, and headaches

Please see Prescribing Information for Norditropin®.

Norditropin® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

 

Novocare_Sogroya_v01

Important Safety Information for Sogroya®

Do not use Sogroya® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
  • you have cancer or other tumors
  • you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes
  • you are a child with closed bone growth plates
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. 
  • It is given by injection under the skin (subcutaneous) and is used to treat adults and children 2.5 years and older who do not make enough growth hormone.

Important Safety Information

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had heart or stomach surgery, trauma, or serious breathing problems
  • have had cancer or any tumor
  • have diabetes
  • have adrenal gland problems
  • are taking replacement therapy with glucocorticoids
  • have thyroid gland problems
  • have liver problems
  • are a child with a history of worsening of curvature of the spine (scoliosis)
  • are pregnant or plan to become pregnant. It is not known if Sogroya® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if Sogroya® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya® while you breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya® may affect the way some medicines work, and some medicines may affect how Sogroya® works.

How should I use Sogroya®?

  • Use Sogroya® exactly as your healthcare provider tells you to
  • Use Sogroya® 1 time each week
  • If you miss a dose of Sogroya®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
  • If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
  • Sogroya® pens are for use by 1 person only
  • Do not share your Sogroya® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. You or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
  • new or worsening high blood sugar or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya®
  • increase in pressure in the skull. If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
  • serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
  • your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
  • decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
  • severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
  • loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya®
  • worsening of curvature of the spine in children (scoliosis)
  • hip and knee pain or a limp in children (slipped capital femoral epiphysis)
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
  • increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

The most common side effects of Sogroya® in children include: common cold, headache, fever, pain in extremity, and reaction to injection

The most common side effects of Sogroya® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), vomiting, high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Please see Prescribing Information for Sogroya®.

Sogroya® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.